• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by VectivBio Holding AG

    6/5/23 4:12:06 PM ET
    $VECT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VECT alert in real time by email
    SC 13G 1 vectivbio13g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    VectivBio Holding AG

    (Name of Issuer)

     

     

    Ordinary Shares, nominal value of CHF 0.05 per share

    (Title of Class of Securities)

     

     

    H9060V101

    (CUSIP Number)

     

     

    May 25, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. H9060V101

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,462,538

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,462,538

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,462,538

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.1%

     

    12. Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. H9060V101

     

     

    1.Names of Reporting Persons.


    Beryl Capital Management LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,462,538

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,462,538

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,462,538

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.1%

     

    12. Type of Reporting Person (See Instructions) IA, PN

     

     3 
    CUSIP No. H9060V101

     

     

    1.Names of Reporting Persons.


    Beryl Capital Partners II LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)          

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,022,897

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,022,897

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,022,897

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 6.4%

     

    12. Type of Reporting Person (See Instructions) PN

     

     4 
    CUSIP No. H9060V101

     

    1.Names of Reporting Persons.


    David A. Witkin

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)     X     

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 4,462,538

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 4,462,538

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,462,538

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.1%

     

    12. Type of Reporting Person (See Instructions) IN, HC

     

     5 
    CUSIP No. H9060V101

    Item 1.

     

    (a)Name of Issuer

    VectivBio Holding AG

     

    (b)Address of Issuer's Principal Executive Offices

    Aeschenyorstadt 36, 4051 Basel, Switzerland

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at:

    225 Avenue I, Suite 205, Redondo Beach, CA 90277

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Ordinary Shares, nominal value of CHF 0.05 per share (the "Stock").

     

    (e)The CUSIP number of the Issuer is: H9060V101
     6 
    CUSIP No. H9060V101

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 62,806,038 Ordinary Shares outstanding as of May 17, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Beryl is the investment adviser to the Partnership and other private investment funds (collectively, the “Funds”) and other accounts. Beryl is the general partner of Beryl GP, which is also the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl and Beryl GP. The Funds hold the Stock for the benefit of their investors, and the Funds and Beryl’s other clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock. Other than the Partnership, no individual client's holdings of the Stock are more than five percent of the outstanding Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Material to Be Filed as Exhibits

    Exhibit A Joint Filing Agreement.

    Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. H9060V101

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 5, 2023

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson  
      Chief Operating Officer and CFO       Andrew Nelson  
            Chief Operating Officer and CFO  
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By: /s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    
     8 
    CUSIP No. H9060V101

     

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

     

    Dated: June 5, 2023

     

    BERYL CAPITAL MANAGEMENT LLC  

    BERYL CAPITAL MANAGEMENT LP

     

          By: Beryl Capital Management LLC
            General Partner
    By: /s/ Andrew Nelson      
      Andrew Nelson     By: /s/ Andrew Nelson  
      Chief Operating Officer and CFO       Andrew Nelson  
            Chief Operating Officer and CFO  
    BERYL CAPITAL PARTNERS II LP    
         
    By: Beryl Capital Management LP   /s/ David A. Witkin
    General Partner   David A. Witkin
         
    By: Beryl Capital Management LLC    
    General Partner    
         
    By:/s/ Andrew Nelson    
    Andrew Nelson    
    Chief Operating Officer    

     

     

    Get the next $VECT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VECT

    DatePrice TargetRatingAnalyst
    12/13/2022$18.00Buy
    Jefferies
    7/1/2022$23.00Overweight
    Piper Sandler
    More analyst ratings

    $VECT
    SEC Filings

    See more
    • SEC Form EFFECT filed by VectivBio Holding AG

      EFFECT - VectivBio Holding AG (0001836379) (Filer)

      7/24/23 12:15:14 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by VectivBio Holding AG

      EFFECT - VectivBio Holding AG (0001836379) (Filer)

      7/24/23 12:15:16 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by VectivBio Holding AG

      EFFECT - VectivBio Holding AG (0001836379) (Filer)

      7/24/23 12:15:18 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VECT
    Leadership Updates

    Live Leadership Updates

    See more
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments

    $VECT
    Financials

    Live finance-specific insights

    See more
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

      - Transaction Advances Ironwood's Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF - - Orphan Drug Designation Received for Treatment of Adult Patients with SBS-IF; Topline Results of Phase 3 Trial Expected by the End of 2023 - - Ironwood to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of VectivBio for $17.00 per Share - - Ironwood to Host Conference Call and Webcast Today at 8:30 a.m. ET - Ironwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, an

      5/22/23 6:57:00 AM ET
      $IRWD
      $VECT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023

      BASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced they will report financial results for the full year ended December 31, 2022 and provide a business update on Wednesday, April 19, 2023 at 8:00 a.m. ET. A live webcast will be accessible under ‘Events & Presentations' in the ‘Investors & Media' section of VectivBio's website at ir.vectivbio.com. An archived replay of the webcast will be available on VectivBio's website approximately two hours after the conference call and will be available for thirty days

      4/12/23 8:00:00 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VECT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Memo Therapeutics AG appoints Paul Carter as Chairperson

      PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

      7/8/24 7:00:00 AM ET
      $IMTX
      $IRWD
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments

    $VECT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on VectivBio with a new price target

      Jefferies initiated coverage of VectivBio with a rating of Buy and set a new price target of $18.00

      12/13/22 9:20:32 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on VectivBio with a new price target

      Piper Sandler initiated coverage of VectivBio with a rating of Overweight and set a new price target of $23.00

      7/1/22 7:43:59 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink initiated coverage on VectivBio Holding with a new price target

      SVB Leerink initiated coverage of VectivBio Holding with a rating of Outperform and set a new price target of $28.00

      5/4/21 7:12:31 AM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VECT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by VectivBio Holding AG (Amendment)

      SC 13G/A - VectivBio Holding AG (0001836379) (Subject)

      2/14/24 12:29:44 PM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by VectivBio Holding AG

      SC 13D - VectivBio Holding AG (0001836379) (Subject)

      7/7/23 4:21:49 PM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by VectivBio Holding AG

      SC 13G - VectivBio Holding AG (0001836379) (Subject)

      6/5/23 4:12:06 PM ET
      $VECT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care